SEC-sourced researchBeta
LYEL
Lyell Immunopharma, Inc.
Company comparison ↗
Data passport
- CIK
- 0001806952
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 10, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 130,000.0000 | Mar 12, 2026 |
| December 2024 | 61,000.0000 | Mar 12, 2026 |
| December 2025 | 36,000.0000 | Mar 12, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 36,000.0000 | -274,448,000.0000 | -150,024,000.0000 | 340,052,000.0000 | 91,850,000.0000 | Mar 12, 2026 |
| December 2024 | 61,000.0000 | -342,994,000.0000 | -162,394,000.0000 | 490,859,000.0000 | 108,035,000.0000 | Mar 12, 2026 |
| December 2023 | 130,000.0000 | -234,632,000.0000 | -163,694,000.0000 | — | — | Mar 12, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $36K | December 2025 | Mar 12, 2026 | 10-K |
| Previous period revenueRevenues | $61K | December 2024 | Mar 12, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$274.45M | December 2025 | Mar 12, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$150.02M | December 2025 | Mar 12, 2026 | 10-K |
| Total assetsAssets | $340.05M | December 2025 | Mar 12, 2026 | 10-K |
| Total liabilitiesLiabilities | $91.85M | December 2025 | Mar 12, 2026 | 10-K |